Hippuric acid

Hippuric acid
Product Name Hippuric acid
CAS No.: 495-69-2
Catalog No.: CFN70124
Molecular Formula: C9H9NO3
Molecular Weight: 179.1 g/mol
Purity: >=98%
Type of Compound: Alkaloids
Physical Desc.: Powder
Source:
Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
Price: $30/20mg
Hippuric Acid as a a major modifier of calcium oxalate (CaOx) formation, it inhibits CaOx growth and considerably enhances the CaOx solubility in artificial urine.
Inquire / Order: manager@chemfaces.com
Technical Inquiries: service@chemfaces.com
Tel: +86-27-84237783
Fax: +86-27-84254680

Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
  • Biofactors.2018, 44(2):168-179
  • Molecules.2019, 24(11):E2044
  • Pharmaceutics.2022, 14(3):564.
  • Int J Mol Sci.2022, 23(23):14545.
  • Molecules2022, 27(12):3903.
  • Agronomy2020, 10(3),388.
  • Biomed Pharmacother.2020, 131:110673.
  • Phytochem Anal.2021, 32(6):970-981.
  • Life Sci.2023, 332:122107.
  • Int J Mol Sci.2023, 24(6):5769.
  • Tectoridin

    Catalog No: CFN99921
    CAS No: 611-40-5
    Price: $50/20mg
    N-trans-caffeoyltyramine

    Catalog No: CFN95265
    CAS No: 103188-48-3
    Price: $318/5mg
    Pinoresinol 4-O-beta-D-glucopyranoside

    Catalog No: CFN97180
    CAS No: 69251-96-3
    Price: $100/20mg
    5'-Guanylic acid

    Catalog No: CFN91721
    CAS No: 85-32-5
    Price: $30/20mg
    Demethylzeylasteral

    Catalog No: CFN90136
    CAS No: 107316-88-1
    Price: $40/20mg
    Xenobiotica, 1998, 28(5):527-537.
    Effect of diet on the urinary excretion of hippuric acid and other dietary-derived aromatics in rat. A complex interaction between diet, gut microflora and substrate specificity.[Reference: WebLink]

    METHODS AND RESULTS:
    1. A combined in vivo and in vitro study has been devised to investigate an observation, obtained by 1H NMR of urine, that AlpfAp SD (Wistar derived) rats kept under standard husbandry conditions did not excrete urinary Hippuric acid (HA). meta-(hydroxyphenyl)propionic acid {m-HPPA} was identified as the major aromatic component inurine samples lacking HA. 2. Examination of urine from Alp:APfSD and Zücker (obese negative) rats fed various diets showed that the lack of HA/presence of m-HPPA was due to diet and not to the strain of animal.This observation was reinforced by the demonstration that the administration of benzoic acid (BA) to rats not previously excreting urinary HA resulted in the return of this component to the urinary excretion profile. Thus rats receiving the standard diet were still capable of glycine conjugation. 3. Changing the diet of rats excreting m -HPPA led to the cessation of m-HPPA excretion and the return of HA urine excretion. Interestingly, switching back to the original diet did not cause the loss of HA and the re-emergence of m-HPPA. 4. In vitro studies on the two enzyme systems responsible for glycine conjugation (benzoyl CoA:synthetase and benzoyl CoA:glycine N-acyltransferase) in isolated liver mitochondria showed that m-HPPA did not inhibit either enzyme. However, m-HPPA was not found to be a substrate for the first reaction step explaining why it was found in the urine as the free acid and not as a glycine conjugate. 5. The absence and presence of m-HPPA and Hippuric acid is suggested to be due to a combination of differences in dietary precursors of substrates for glycine conjugation and a dietary dependent redistribution of theintestinalmicroflora responsible for breakdownof plant phenolics and aromatic amino acids.
    CONCLUSIONS:
    Taken collectively this study emphasises how a simple diet change can cause a profound change in metabolism.
    Canadian Journal of Chemistry, 1975, 53(13):1993-2004.
    Reversible Inhibition of Carboxypeptidase A. IV. Inhibition of Specific Esterase Activity by Hippuric Acid and Related Species and other Amino Acid Derivatives and a Comparison with Substrate Inhibition.[Reference: WebLink]

    METHODS AND RESULTS:
    The anions of each of the following carboxylic acids exhibit uncompetitive inhibition of the hydrolysis of O-hippuryl-L-3-phenyllactic acid by bovine carboxypeptidase A at pH 7.5, 25°, ionic strength 0.2: Hippuric acid, p-chloro- and p-nitroHippuric acids, hippurylglycine, carbobenzoxyglycine, phenaceturic acid, N'-(3-phenylpropanoyl)glycine, benzoxyacetic acid, 3-benzoylpropanoic acid, and O-hippuryl-D-mandelic acid. In each case, this uncompetitive inhibition is consistent with the ordered binding of substrate and inhibitor to the enzyme; i.e. the inhibitor binds to E.S but not to the free enzyme. Evidence is presented for the binding site for uncompetitive inhibitors being the same as for inhibitory ester substrate molecules. Comparison of the specificities of uncompetitive inhibitors and esters which display substrate inhibition provides evidence for a critical conformational change which controls the binding of uncompetitive inhibitors and inhibitory substrate molecules.D-Phenylalanine, D-leucine, D-p-nitrophenylalanine, glycyl-L-tyrosine, glycyl-L-phenylalanine, and glycyl-L-leucine are competitive inhibitors of the enzymic hydrolysis of O-hippuryl-L-3-phenyllactic acid, whereas the N-chloroacetyl derivatives of L-tyrosine, L-phenylalanine, and L-leucine are noncompetitive inhibitors. For the above D-amino acids, glycyl dipeptides, and N-chloroacetyl amino acids, the phenylalanine derivative in each case is a considerably stronger inhibitor than the corresponding leucine derivative. This preference is similar to that observed for the binding of peptide substrates but the reverse of that observed for ester substrates and simple mono- and dicarboxylate ion inhibitors.The peptide substrates carbobenzoxyglycylglycyl-L-phenylalanine and N-chloroacetyl-L-phenylalanine are noncompetitive inhibitors of the enzymic hydrolysis of O-hippuryl-L-3-phenyllactic acid.
    CONCLUSIONS:
    This clearly demonstrates the presence of different ester and peptide binding sites in this enzyme, which is consistent with conclusions from recent studies in other laboratories.
    Clin Chem Lab Med,2001 Mar;39(3):218-22.
    Hippuric Acid as a Modifier of Calcium Oxalate Crystallisation.[Pubmed: 11350018]
    Hippuric acid (HA) originating from the conjugation of benzoic acid with glycine is a physiological component of human urine. Findings suggest that HA inhibits calcium oxalate (CaOx) growth and considerably enhances the CaOx solubility in artificial urine. Thus, it is assumed that HA is a major modifier of CaOx formation. However, only a slight CaOx growth inhibition of 1-8% was also reported. These values were also derived from artificial urine. The key mechanism, which led HA to be of interest in urolithiasis research is the fact that in presence of Ca2+ ions HA can form a hippurate complex. By forming such a complex, Ca2+ concentration in urine decreases, and as a consequence, CaOx formation is inhibited. This study was performed in order to clarify the role of HA in native and artificial urine.
    METHODS AND RESULTS:
    Biochemical analyses to calculate the relative CaOx supersaturations and crystallisation experiments using an in-line laser probe were examined. BONN Risk Indices indicating the risk of CaOx crystallisation were calculated from the results of the crystallisation experiments. The results obtained from artificial as well as from native urines showed that HA has no significant effects on CaOx formation.
    CONCLUSIONS:
    We suggest that HA plays only a minor role as a crystallisation modifier in human urine.
    Pd-C-II

    Catalog No: CFN95003
    CAS No: N/A
    Price: $358/5mg
    Patulitrin

    Catalog No: CFN95153
    CAS No: 19833-25-1
    Price: $318/10mg
    Momordicine II

    Catalog No: CFN95167
    CAS No: 91590-75-9
    Price: $318/10mg
    (3R,5S,E)-1,7-Diphenylhept-1-ene-3,5-diol

    Catalog No: CFN95227
    CAS No: 232261-31-3
    Price: $318/5mg
    Polygalacin D2

    Catalog No: CFN95241
    CAS No: 66663-92-1
    Price: $413/5mg
    9,11-Dehydro-beta-boswellic acid

    Catalog No: CFN95335
    CAS No: 471-65-8
    Price: $318/5mg
    Caffeoylcalleryanin

    Catalog No: CFN95532
    CAS No: 20300-49-6
    Price: $318/10mg
    New compound 20

    Catalog No: CFN95545
    CAS No: N/A
    Price: $413/5mg
    Calleryanin

    Catalog No: CFN95556
    CAS No: 20300-53-2
    Price: $318/5mg
    New compound 21

    Catalog No: CFN95560
    CAS No: N/A
    Price: $413/5mg